Assyro AI

FDA Orange Book · active-ingredient family

Dinoprostone

Dinoprostone is approved in 3 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:CERVIDIL · NDA 020411

3

Brand (NDA)

0

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · gel, insert, extended release, suppository

ProductApplicantApplicationTEApproved
CERVIDILRLDFERRING PHARMS INCNDA 020411Mar 30, 1995
PREPIDILRLDPFIZERNDA 019617Dec 09, 1992
PROSTIN E2RLDPFIZERNDA 017810Approved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Dinoprostone — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.